San Diego—Lenalidomide maintenance extended progression-free survival (PFS) after first-line therapy in high-risk chronic lymphocytic leukemia (CLL) patients and after second-line therapy in CLL patients with at least a partial response to their last regimen, during two Phase III studies. Both trials were stopped early by their data and safety monitoring committees because of the large advantage of lenalidomide maintenance at an interim analysis.
In the trial evaluating lenalidomide